Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4578 plus letrozole and CDK4/6 inhibitor in first-line HR-positive HER2-negative metastatic breast cancer
jRCT2031210364Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ONO-4578 in breast cancer (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Safety and tolerability. Started Nov 2021; status: completed.
02
Drugs
ONO-4578
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031210364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210364.